Peginterferon Alfa-2a/Ribavirin for 48 or 72 Weeks in Hepatitis C Genotypes 1 and 4 Patients With Slow Virologic Response
- 28 February 2010
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 138 (2) , 503-512.e1
- https://doi.org/10.1053/j.gastro.2009.10.058
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- 612 WEEK 8 HCV-RNA IS THE OPTIMAL PREDICTOR OF RELAPSE IN NON-RVR PATIENTS WITH GENOTYPE 1/4 RANDOMISED TO 48 OR 72 WEEKS PEG-IFN ALFA-2A PLUS RBVJournal of Hepatology, 2009
- Diagnosis, management, and treatment of hepatitis C: An update # † ‡Hepatology, 2009
- Peginterferon Alfa-2a and Ribavirin for 24 Weeks in Hepatitis C Type 1 and 4 Patients With Rapid Virological ResponseGastroenterology, 2008
- Economic impact of extended treatment with peginterferon α‐2a and ribavirin for slow hepatitis C virologic respondersJournal of Viral Hepatitis, 2008
- Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trialHepatology, 2007
- Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic responseHepatology, 2007
- Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1–infected slow respondersHepatology, 2007
- Peginterferon-Alfa2a Plus Ribavirin for 48 Versus 72 Weeks in Patients With Detectable Hepatitis C Virus RNA at Week 4 of TreatmentGastroenterology, 2006
- Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapyHepatology, 2006
- Extended Treatment Duration for Hepatitis C Virus Type 1: Comparing 48 Versus 72 Weeks of Peginterferon-Alfa-2a Plus RibavirinGastroenterology, 2006